Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Emcure Pharmaceuticals Ltd
EMCUREEmcure Pharmaceuticals Limited engages in the developing, manufacturing, and marketing pharmaceutical products worldwide. It offers products in various therapeutic areas, such as gynecology, cardiovascular, anti-infectives, HIV antivirals, respiratory, gastrointestinal, pain and analgesics, blood related, oncology/anti-neoplastics, anti-diabetic, hormones, neurology/central nervous system, dermatology, and other areas, as well as vitamins, minerals, and nutrients. The company also develops products across various platforms, including chiral molecules, complex APIs, orals, iron products, photo-chemistry products, liposomal and lyophilized injectables, high potency drugs, biotherapeutics, and novel drug delivery systems. It provides its products under Orofer, Bevon, Maxtra, Zostum, Metpure, and Eslo brand names. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India. Address: Plot No. P-1 and P-2, Pune, India, 411057
Analytics
Zielpreis von Wall Street
132 977.79 INRKGV
54.2911Dividendenrendite
–Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen EMCURE
Dividenden-Analyse EMCURE
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
–Verlauf der Dividende EMCURE
Bewertung der Aktie EMCURE
Finanzen EMCURE
Ergebnisse | 2019 | Dynamik |